Pharmafile Logo
Pharmafocus logo
Advanced Search

Celgene

Showing 8 posts of 128 posts found.

lechleiter_john_300dpi

Lilly’s John Lechleiter elected as PhRMA Board chairman

April 17, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, John Lechleiter, Pfizer, Sanofi, lilly

John Lechleiter, chairman, president and chief executive of Lilly has been elected chairman of the Pharmaceutical Research and Manufacturers of …

Appointment

Richard Barker elected to Celgene’s board of directors

January 24, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing ABPI, Celgene, Richard Barker

Celgene, the biopharma firm specialising in cancer and inflammatory diseases, has elected Richard Barker to its board of directors. Dr …

Appointment

Celgene appoints Dr David Gillen as its UK and Ireland medical director

January 9, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Celgene

Celgene has appointed former Pfizer man Dr David Gillen as its new UK and Ireland medical director. Gillen brings much …

Appointment
Willetts opens the new Celgene headquarters

Celgene opens new headquarters in UK

November 21, 2011
Research and Development, Sales and Marketing Celgene

Celgene has opened new UK headquarters in London as its haematology-based business expands. The firm says it has decided to …

News

Vidaza patient access scheme sways NICE

February 17, 2011
Sales and Marketing Celgene, NICE, Vidaza

Celgene’s Vidaza has been recommended by NICE in final draft guidance issued today. Vidaza (azacitidine) is recommended as a treatment …

News

Celgene completes Abraxis takeover

October 15, 2010
Research and Development, Sales and Marketing Abraxane, Abraxis, Celgene, mergers and acquisitions, oncology

Celgene has completed its acquisition of Abraxis BioScience for cash and stock totalling $2.9 billion. The takeover gives the cancer …

News

Vidaza too costly for NICE

March 8, 2010
Sales and Marketing Celgene, NICE, Vidaza

NICE has rejected Celgene’s Vidaza for use on the NHS to treat the rare bone marrow disease myelodysplastic syndrome. The …

News

Celgene

January 1, 2010
Research and Development, Sales and Marketing Abraxane, Celgene, Revlimid, Thalidomide

Founded in 1986, Celgene was created as a spin off from the Celanese Corporation. Two years later, the company received …

Feature

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023